MedTrace Logo

Therapeutic Potential of Topical Latanoprost Acid in Hair Loss - Pilot, Proof-of-concept Study

NCT07412587 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2026-02-17

No results posted yet for this study

Summary

This pilot study evaluates the efficacy, safety, and tolerability of topical latanoprost acid in adult women with female pattern hair loss, with a minority of participants diagnosed with chronic telogen effluvium. In this randomized, double-blind, single-center, dose-ranging trial, participants receive latanoprost acid 0.01%, 0.05%, or 0.1% applied once daily for 6 months; a small vehicle group is included to support masking and assess tolerability. The primary outcome is the within-participant change in target-area hair count (hairs/cm²) from baseline to Month 6. Secondary and exploratory outcomes include follicular-unit distribution (percent of 1-, 2-, and 3-hair units), number of yellow dots, and patient-reported outcomes.

Conditions

  • Androgenetic Alopecia (AGA)
  • Telogen Effluvium
  • Female Pattern Hair Loss, Androgenic Alopecia

Interventions

OTHER

Latanoprost acid-containing cosmetic topical solution

Topical cosmetic solution containing latanoprost acid, evaluated at concentrations of 0.01%, 0.05%, and 0.1% in a vehicle formulation, with a matching vehicle-only cosmetic solution used as placebo comparator. The cosmetic solution was dispensed in identical, coded dropper bottles to maintain blinding. Participants applied the assigned cosmetic solution once daily for 6 months to the androgen-dependent scalp area affected by thinning hair, distributing approximately 2-3 mL evenly, avoiding runoff, and refraining from washing the treated area for at least 8 hours post-application. Use of concomitant hair-loss treatments was prohibited and usual hair-care routines were kept constant during the study.

OTHER

Vehicle cosmetic topical solution (placebo comparator)

Matching vehicle-only cosmetic topical solution without latanoprost acid. The product was dispensed in identical, coded dropper bottles to maintain blinding. Participants applied the vehicle cosmetic solution once daily for 6 months to the androgen-dependent scalp area affected by thinning hair, distributing approximately 2-3 mL evenly, avoiding runoff, and refraining from washing the treated area for at least 8 hours post-application. Concomitant hair-loss treatments were prohibited and usual hair-care routines were kept constant during the study.

Sponsors & Collaborators

  • Medical University of Warsaw

    lead OTHER

Principal Investigators

  • Katarzyna A Koziak, Professor · Medical University of Warsaw

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-08
Primary Completion
2016-07-08
Completion
2016-07-08

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07412587 on ClinicalTrials.gov